KYTX (STOCKS)
Kyverna Therapeutics, Inc. Common Stock
$9.490000
+0.540000 (+6.03%)
Prev close: $8.950000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Warner Biddle
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $573.27M
- Employees
- 129
- P/E (TTM)
- -2.60
- P/B (TTM)
- 2.47
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.80 | $-0.88 | +0.0755 | +8.62% |
|
Sep 2025 (Q3)
|
$-0.85 | $-0.99 | +0.1411 | +14.24% |
|
Jun 2025 (Q2)
|
$-0.97 | $-1.06 | +0.0942 | +8.85% |
|
Mar 2025 (Q1)
|
$-1.03 | $-1.14 | +0.1056 | +9.30% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $8.52M |
| Operating Expenses | $169.83M |
| Research and Development | $133.72M |
| Other Operating Expenses | $36.11M |
| Operating Income/Loss | -$169.83M |
| Income/Loss From Continuing Operations After Tax | -$161.31M |
| Income/Loss From Continuing Operations Before Tax | -$161.31M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$161.31M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$161.31M |
| Net Income/Loss Available To Common Stockholders, Basic | -$161.31M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.64 |
| Diluted Earnings Per Share | -$3.64 |
| Basic Average Shares | 44,259,999 |
| Diluted Average Shares | 44,259,999 |
| Assets | $293.83M |
| Current Assets | $282.95M |
| Cash | $279.30M |
| Other Current Assets | $3.65M |
| Noncurrent Assets | $10.87M |
| Fixed Assets | $1.55M |
| Other Non-current Assets | $9.33M |
| Liabilities | $61.55M |
| Current Liabilities | $36.49M |
| Accounts Payable | $5.31M |
| Other Current Liabilities | $31.18M |
| Noncurrent Liabilities | $25.06M |
| Equity | $232.28M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $232.28M |
| Liabilities And Equity | $293.83M |
| Net Cash Flow From Operating Activities | -$153.71M |
| Net Cash Flow From Operating Activities, Continuing | -$153.71M |
| Net Cash Flow From Investing Activities | $40.02M |
| Net Cash Flow From Investing Activities, Continuing | $40.02M |
| Net Cash Flow From Financing Activities | $141.17M |
| Net Cash Flow From Financing Activities, Continuing | $141.17M |
| Net Cash Flow | $27.47M |
| Net Cash Flow, Continuing | $27.47M |
| Comprehensive Income/Loss | -$161.32M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$161.32M |
| Other Comprehensive Income/Loss | -$161.32M |
| Other Comprehensive Income/Loss Attributable To Parent | -$8.00K |